A5036762729- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Pancreatitis Pathology and Treatment
- Neuroendocrine Tumor Research Advances
- TGF-β signaling in diseases
- Gallbladder and Bile Duct Disorders
- Cancer-related gene regulation
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Cells and Metastasis
- BRCA gene mutations in cancer
- Colorectal Cancer Screening and Detection
- Radiomics and Machine Learning in Medical Imaging
- Renal cell carcinoma treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Limits and Structures in Graph Theory
- Colorectal Cancer Treatments and Studies
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Organ Transplantation Techniques and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Genetics, Bioinformatics, and Biomedical Research
Duke University
2019-2025
Duke Medical Center
2019-2025
Durham Technical Community College
2022-2024
Duke Cancer Institute
2021-2024
Duke University Hospital
2019-2024
Duke Institute for Health Innovation
2023
Cancer Institute (WIA)
2022
Memorial Sloan Kettering Cancer Center
2007-2021
Duke University Health System
2021
Eastern Hepatobiliary Surgery Hospital
2019
Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can detect eight common types through assessment of the levels circulating proteins and mutations in cell-free DNA. We applied this test, called CancerSEEK, 1005 patients with nonmetastatic, clinically detected cancers ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast. CancerSEEK tests were positive median 70% types. The sensitivities ranged from 69 98% for five (ovary, esophagus)...
<h3>Importance</h3> Unresectable intrahepatic cholangiocarcinoma (IHC) carries a poor prognosis, with median overall survival (OS) of 11 months. Hepatic arterial infusion (HAI) high-dose chemotherapy may have potential benefit in these patients. <h3>Objective</h3> To evaluate clinical outcomes when HAI is combined systemic patients unresectable IHC. <h3>Design, Setting, and Participants</h3> A single-institution, phase 2 trial including 38 was conducted floxuridine plus gemcitabine...
Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown.This bi-institutional study of patients with confirmed iCCA (n = 412) used targeted next-generation sequencing primary tumors to define associations among genetic alterations, clinicopathological variables, outcome. The most common oncogenic were isocitrate dehydrogenase 1 (IDH1; 20%), AT-rich interactive domain-containing protein 1A...
The impact of margin width on overall survival (OS) in the context other prognostic factors after resection for colorectal liver metastases is unclear. We evaluated relationship between and OS utilizing high-resolution histologic distance measurements.A single-institution prospectively maintained database was queried all patients who underwent an initial complete 1992 2012. R1 defined as tumor cells at (0 mm). R0 further divided into 3 groups: 0.1 to 0.9 mm, 1 9 10 mm or greater.A total 4915...
In Brief Objective: To identify factors associated with survival in Merkel cell carcinoma (MCC). Background: is a rare cutaneous neoplasm. Staging and treatment are based on studies, which incompletely characterize the disease. Methods: Review of prospective database was performed. Overall (OS) estimated by Kaplan-Meier method. Disease-specific death (DSD) analyzed competing risks Factors OS DSD were determined log-rank test Gray's test, respectively. Results: A total 500 patients MCC...
Background and Objective: Robotic distal pancreatectomy (DP) is an emerging attractive approach, but its role compared with laparoscopic or open surgery remains unclear. Benchmark values are novel objective tools for such comparisons. The aim of this study was to identify benchmark cutoffs many outcome parameters DP without splenectomy beyond the learning curve. Methods: This analyzed outcomes from international expert centers patients undergoing robotic malignant benign lesions. After...
We aimed to determine the severity and co-occurrence of established potential paraneoplastic conditions in pancreatic cancer (weight loss, new onset diabetes, fatigue, depression) their relation patient characteristics.Using information from personal interviews with 510 cases 463 controls, we obtained adjusted odds ratios for weight long-term new-onset depression before diagnosis. Among cases, investigated extent which these factors occurred together characteristics those reporting them.The...
We sought to comprehensively profile tissue and cyst fluid in patients with benign, precancerous, cancerous conditions of the pancreas characterize intrinsic pancreatic microbiome.
The histopathologic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complicates the prediction pancreatic ductal adenocarcinoma (PDAC) risk. Intratumoral regions pancreaticobiliary (PB), intestinal (INT), and gastric foveolar (GF) epithelium may occur with either low-grade dysplasia (LGD) or high-grade (HGD). We used digital spatial RNA profiling dysplastic (83 regions) from surgically resected IPMN tissues (12 patients) to differentiate subtypes predict genes associated...
PURPOSE The benefit of adjuvant therapy for intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) remains unclear because severely limited evidence. Although biologically distinct entities, practices IPMN-derived PDAC are largely founded on intraepithelial neoplasia-derived PDAC. We aimed to evaluate the role chemotherapy in METHODS This international multicenter retrospective cohort study (2005-2018) was conceived at Verona Evidence-Based Medicine...
772 Background: The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) to conventional cytotoxic therapy underscores the need for advances in targeted molecular therapeutics. Previous studies have reported approximately 2% PDAC patients with HER2 gene amplification. While anti- cancer has yielded success other disease sites, it had minimal benefit PDAC. Multiple isoforms exist that are generated either by loss exon 16 ( d16 ), or through N-terminal truncations p95 ). These...
Abstract Background A growing number of centers offer hepatic artery infusion pump (HAIP) chemotherapy for advanced liver malignancies. While small series have demonstrated feasibility robotic HAIP placement, comparison outcomes with open placement is lacking. We compared after versus placement. Methods retrospectively reviewed without concurrent hepatectomy at Memorial Sloan Kettering Cancer Center from 1 January 2011 to 15 September 2022, and Duke Health November 2018 18 May 2023. Patients...
Objective: Develop machine learning (ML) models to predict postsurgical length of stay (LOS) and discharge disposition (DD) for multiple services with only the data available at time case posting. Background: Surgeries are scheduled largely based on operating room resource availability little attention downstream such as inpatient bed care needs after hospitalization. Predicting LOS DD posting could support allocation earlier planning. Methods: This retrospective study included 63,574 adult...
Abstract Introduction While KRAS mutations represent the primary oncogenic driver in pancreatic ductal adenocarcinoma (PDAC), association between codon-specific alterations and patient outcomes remains poorly elucidated, largely due to a lack of datasets coupling genomic profiling with rich clinical annotations across disease stages. Patients Methods We utilized AACR’s GENIE Biopharma Consortium Pancreas v1.2 dataset test associating clinicogenomic features PDAC patients diagnosed localized...